Tozun N.,Acibadem University |
Sezgin O.,Mersin University |
Gulsen M.,University of Gaziantep |
Kacar S.,Turkiye Yuksek Ihtisas Research and Training Hospital |
And 9 more authors.
Turkish Journal of Gastroenterology | Year: 2012
Background/aims: Pegylated alfa interferon is the only immunomodulatory drug licensed for hepatitis B. We evaluated the safety and tolerability of peginterferon alfa-2a (40KD) in patients with chronic hepatitis B. Materials and Methods: A total of 113 chronic hepatitis B patients under peginterferon alfa-2a (40KD; 180 μg/week) treatment were included in this multicenter, open label, non-interventional study, and 66 patients completed the follow-up period. Vital signs, physical examination and laboratory findings, concomitant medications, and adverse events were recorded. A Quality of Life questionnaire (Short Form-36) was performed twice, at the beginning and at the end of the study. Results: There was no significant difference between initial and last visits in terms of physical examination findings and Short Form-36 scores. A total of 27 adverse events were reported in 15 patients (22.7%), with most of them being mild in intensity (70.4%). The rates of the adverse events were similar in the monotherapy and combination therapy groups (peginterferon alfa-2a + lamivudine, peginterferon alfa-2a + adefovir or peginterferon alfa-2a + entecavir therapy groups), at 23.7% and 14.3%, respectively. The dosage of peginterferon had to be reduced in 3 patients (4.5%) due to thrombocytopenia. Overall patient compliance to treatment was detected as 85.9%. Conclusions: Based on the lack of serious adverse events and absence of impairment in Quality of Life, peginterferon alfa-2a (40KD, 180 μg/week, subcutaneously) treatment for 48 weeks led to a high level of patient compliance and was associated with a high degree of safety and tolerability for the treatment of adult patients with chronic hepatitis B in real-life practice.
The fourier transform infrared (FTIR) spectroscopic and mass spectrometric metabolomics studies of ankaferd hemostat [Ankaferd Hemostatin Fourier Transform Infrared (FTIR) Spektroskopik ve Kütle Spektrometrik Metabolomik Incelemesi]
Demiralp D.O.,Ankara University |
Igci N.,Ankara University |
Ozturk Y.,INC Research |
Beyazit Y.,Turkiye Yuksek Ihtisas Research and Training Hospital |
Haznedaroglu I.C.,Hacettepe University
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi | Year: 2013
Ankaferd is a traditional folkloric medicine that has been used in Anatolia as a hemostatic agent for centuries. Ankaferd Blood Stopper (ABS) is comprised of a standardized plant extracts of T. vulgaris, G. glabra, V. vinifera, A.officinarum and U. Dioica. ABS modulates cellular apoptotic responses to hemorrhagic stress, as well as the hemostatic hemodynamic activity. Although the effects of ABS mainly depends upon the formation of an encapsulated protein network representing focal points for vital erythrocyte aggregation, integration of the functional proteomics, transcriptomics, and metabolomics will be important for detecting the exact 'mechanism- of-action' of ABS. In order to analyse the fourier transform infrared (FTIR) spectroscopic and mass spectrometric metabolomics, we prepared two-dimensional protein samples and used a Tensor 27 FTIR spectrometer, equipped with a high throughput extension (HTS-XT) accessory. The derivative spectra of metabolomic content of ABS and mass spectrometric and FTIR results were demonstrated. Biological fatty acids such as octanoic acid, heptanoic acid, decanoic acid, eicosanoic acid, octadecanoic acid, hexadecanoic acid, and others have been detected in the metabolomics of ABS. Our results about mass spectrometry and FTIR spectroscopy analyses ABS content within the many crossroads of hemostasis, infection, and neoplasia. Metabolomics studies may shed further light and represent a novel starting point on that perspective for the new avenues of ABS.
PubMed | Cumhuriyet University and Turkiye Yuksek Ihtisas Research and Training Hospital
Type: Journal Article | Journal: Biomedical reports | Year: 2017
Matrix metalloproteinase (MMP)-3 and MMP-9 polymorphisms are characterized by plaque stability in coronary arteries. The aim of the current study was to investigate the